Ashiwel S. Undieh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ashiwel S. Undieh has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
Eitan Friedman
4 shared publicationsJie Bai
Laboratory of Neurogenomics and Proteomics, Department of Biomedical Sciences, University of Maryland, Baltimore, Maryland, United States of America
3 shared publications- Michael S. Lidow
Department of Biomedical Sciences and Program of Neuroscience, University of Maryland, Room 5-A-12, HHH, 666 W. Baltimore Street, Baltimore, MD 21201, USA
3 shared publications - Sandra Panchalingam
Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, United States of America
3 shared publications Elena Deliu
Department of Pharmacology, Temple University School of Medicine, Philadelphia, Pennsylvania 19140, USA
2 shared publications- Eugen Brailoiu
Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA 19140, USA
2 shared publications
Latest Publications
- 23 October 2014
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 11 (12) , 4415-4424
Stable and Efficient Transfection of siRNA for Mutated KRAS Silencing Using Novel Hybrid Nanoparticles
SiRNA is currently the most widely studied form of RNAi, and it has promising therapeutic potential not just in cancer but also in other diseases such as autoimmune and infectious diseases. However, efficient delivery of siRNA to target cells is being limited by lack of an effective delivery system that ensures efficient transfection into cells while protecting the encapsulated siRNA from nuclease. We hypothesized that a hybrid nanoparticle system composed of human IgG and poloxamer-188, a stealth polymer, will efficiently deliver mutated KRAS siRNA to A549 cells, leading to an efficient knockdown of mutated siRNA while protecting the siRNA from serum nuclease. We also hypothesized that the nanoparticles will not elicit an immunostimulatory effect in murine macrophages and also avoid clearance by macrophages. These nanoparticles were found to efficiently deliver siRNA to the cytoplasm and nuclease of A549 cells in a controlled and sustained manner while avoiding recycling by endosomes. An effective knockdown of mutated KRAS was achieved, which subsequently led to an increased sensitivity to erlotinib. These nanoparticles successfully avoided uptake by murine macrophages and reduced immune responses normally associated with siRNA/nanoparticle therapy. These results demonstrate that the novel hybrid nanoparticles could potentially serve as a platform for efficient delivery of siRNA to cells for stable gene knockdown.
- 23 October 2014
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 11 (12) , 4415-4424
Stable and Efficient Transfection of siRNA for Mutated KRAS Silencing Using Novel Hybrid Nanoparticles
SiRNA is currently the most widely studied form of RNAi, and it has promising therapeutic potential not just in cancer but also in other diseases such as autoimmune and infectious diseases. However, efficient delivery of siRNA to target cells is being limited by lack of an effective delivery system that ensures efficient transfection into cells while protecting the encapsulated siRNA from nuclease. We hypothesized that a hybrid nanoparticle system composed of human IgG and poloxamer-188, a stealth polymer, will efficiently deliver mutated KRAS siRNA to A549 cells, leading to an efficient knockdown of mutated siRNA while protecting the siRNA from serum nuclease. We also hypothesized that the nanoparticles will not elicit an immunostimulatory effect in murine macrophages and also avoid clearance by macrophages. These nanoparticles were found to efficiently deliver siRNA to the cytoplasm and nuclease of A549 cells in a controlled and sustained manner while avoiding recycling by endosomes. An effective knockdown of mutated KRAS was achieved, which subsequently led to an increased sensitivity to erlotinib. These nanoparticles successfully avoided uptake by murine macrophages and reduced immune responses normally associated with siRNA/nanoparticle therapy. These results demonstrate that the novel hybrid nanoparticles could potentially serve as a platform for efficient delivery of siRNA to cells for stable gene knockdown.
- Open Access
- 1 November 2012
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 287 (49) , 41023-41031
Intracellular Endothelin Type B Receptor-driven Ca2+ Signal Elicits Nitric Oxide Production in Endothelial Cells
- 1 November 2012
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 287 (49) , 41023-41031
Open AccessIntracellular Endothelin Type B Receptor-driven Ca2+ Signal Elicits Nitric Oxide Production in Endothelial Cells
- 21 December 2011
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 123 (1-3) , 277-281
Agonist-selective effects of opioid receptor ligands on cytosolic calcium concentration in rat striatal neurons
- 21 December 2011
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 123 (1-3) , 277-281
Agonist-selective effects of opioid receptor ligands on cytosolic calcium concentration in rat striatal neurons
- 12 January 2011
- Published by Elsevier in Molecular and Cellular Neuroscience
- Vol. 46 (3) , 645-654
Differential subcellular distribution of rat brain dopamine receptors and subtype-specific redistribution induced by cocaine
- 12 January 2011
- Published by Elsevier in Molecular and Cellular Neuroscience
- Vol. 46 (3) , 645-654
Differential subcellular distribution of rat brain dopamine receptors and subtype-specific redistribution induced by cocaine
- 1 October 2010
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 128 (1) , 37-60
Pharmacology of signaling induced by dopamine D1-like receptor activation
- 1 October 2010
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 128 (1) , 37-60
Pharmacology of signaling induced by dopamine D1-like receptor activation
- Open Access
- 26 September 2010
- Published by Taylor & Francis in Global Health Action
- Vol. 3 (1)
Building capacity for public and population health research in Africa: the consortium for advanced research training in Africa (CARTA) model
Building capacity for public and population health research in Africa: the consortium for advanced research training in Africa (CARTA) model
- 26 September 2010
- Published by Taylor & Francis in Global Health Action
- Vol. 3 (1)
Open AccessBuilding capacity for public and population health research in Africa: the consortium for advanced research training in Africa (CARTA) model
Building capacity for public and population health research in Africa: the consortium for advanced research training in Africa (CARTA) model
- 1 February 2010
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 332 (2) , 463-468
Brain-Derived Neurotrophic Factor Signaling Modulates Cocaine Induction of Reward-Associated Ultrasonic Vocalization in Rats
Cocaine exhibits high liability for inducing addictive behaviors, but the mechanisms of neuroplasticity underlying the behavioral effects remain unclear. As a crucial mediator of neuroplasticity in diverse functional models, brain-derived neurotrophic factor (BDNF) could contribute to the mechanisms of addiction-related neuroplasticity. Here, we addressed the hypothesis that cocaine increases synaptic dopamine, which induces BDNF protein expression to initiate addiction-related behavior in the rat. An enzyme-linked immunosorbent assay was used to measure BDNF protein expression in rat striatal tissues. For behavioral readout, we used a noninvasive measurement system to measure the emission of 50-kHz ultrasonic vocalization (USV), a response that correlates with electrical brain stimulation and conditioned place preference behavior in rodents. A single injection of cocaine significantly increased BDNF protein expression, but this effect was not further augmented by repeated cocaine administration. A single administration of cocaine elicited significant and dose-related USV responses, and the magnitude of the behavior increased with repeated drug administration. R-(+)-7-Chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SCH23390), but not raclopride, significantly attenuated cocaine-induced BDNF protein expression, whereas either the D1-like or D2-like receptor antagonist blocked cocaine-induced USV behavior. Furthermore, significant USV behavior was elicited by the nonselective dopamine agonist, apomorphine, but not by agonists that are selective for D1-like or D2-like receptors. Intracerebroventricular injection of the neurotrophin TrkB receptor inhibitor, K252a, blocked cocaine-induced USV behavior but not locomotor activity. These results suggest that neurotrophin signaling downstream of dopamine receptor function probably constitutes a crucial link in cocaine induction of USV behavior and may contribute to the mechanisms underlying the development of addiction-related behaviors.
- 1 February 2010
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 332 (2) , 463-468
Brain-Derived Neurotrophic Factor Signaling Modulates Cocaine Induction of Reward-Associated Ultrasonic Vocalization in Rats
Cocaine exhibits high liability for inducing addictive behaviors, but the mechanisms of neuroplasticity underlying the behavioral effects remain unclear. As a crucial mediator of neuroplasticity in diverse functional models, brain-derived neurotrophic factor (BDNF) could contribute to the mechanisms of addiction-related neuroplasticity. Here, we addressed the hypothesis that cocaine increases synaptic dopamine, which induces BDNF protein expression to initiate addiction-related behavior in the rat. An enzyme-linked immunosorbent assay was used to measure BDNF protein expression in rat striatal tissues. For behavioral readout, we used a noninvasive measurement system to measure the emission of 50-kHz ultrasonic vocalization (USV), a response that correlates with electrical brain stimulation and conditioned place preference behavior in rodents. A single injection of cocaine significantly increased BDNF protein expression, but this effect was not further augmented by repeated cocaine administration. A single administration of cocaine elicited significant and dose-related USV responses, and the magnitude of the behavior increased with repeated drug administration. R-(+)-7-Chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SCH23390), but not raclopride, significantly attenuated cocaine-induced BDNF protein expression, whereas either the D1-like or D2-like receptor antagonist blocked cocaine-induced USV behavior. Furthermore, significant USV behavior was elicited by the nonselective dopamine agonist, apomorphine, but not by agonists that are selective for D1-like or D2-like receptors. Intracerebroventricular injection of the neurotrophin TrkB receptor inhibitor, K252a, blocked cocaine-induced USV behavior but not locomotor activity. These results suggest that neurotrophin signaling downstream of dopamine receptor function probably constitutes a crucial link in cocaine induction of USV behavior and may contribute to the mechanisms underlying the development of addiction-related behaviors.
- Open Access
- 27 January 2010
- Published by Springer Nature in BMC Neuroscience
- Vol. 11 (1) , 10
Antidepressant stimulation of CDP-diacylglycerol synthesis does not require monoamine reuptake inhibition
Recent studies demonstrate that diverse antidepressant agents increase the cellular production of the nucleolipid CDP-diacylglycerol and its synthetic derivative, phosphatidylinositol, in depression-relevant brain regions. Pharmacological blockade of downstream phosphatidylinositide signaling disrupted the behavioral antidepressant effects in rats. However, the nucleolipid responses were resistant to inhibition by serotonin receptor antagonists, even though antidepressant-facilitated inositol phosphate accumulation was blocked. Could the neurochemical effects be additional to the known effects of the drugs on monoamine transmitter transporters? To examine this question, we tested selected agents in serotonin-depleted brain tissues, in PC12 cells devoid of serotonin transporters, and on the enzymatic activity of brain CDP-diacylglycerol synthase - the enzyme that catalyzes the physiological synthesis of CDP-diacylglycerol.
- 27 January 2010
- Published by Springer Nature in BMC Neuroscience
- Vol. 11 (1) , 10
Open AccessAntidepressant stimulation of CDP-diacylglycerol synthesis does not require monoamine reuptake inhibition
Recent studies demonstrate that diverse antidepressant agents increase the cellular production of the nucleolipid CDP-diacylglycerol and its synthetic derivative, phosphatidylinositol, in depression-relevant brain regions. Pharmacological blockade of downstream phosphatidylinositide signaling disrupted the behavioral antidepressant effects in rats. However, the nucleolipid responses were resistant to inhibition by serotonin receptor antagonists, even though antidepressant-facilitated inositol phosphate accumulation was blocked. Could the neurochemical effects be additional to the known effects of the drugs on monoamine transmitter transporters? To examine this question, we tested selected agents in serotonin-depleted brain tissues, in PC12 cells devoid of serotonin transporters, and on the enzymatic activity of brain CDP-diacylglycerol synthase - the enzyme that catalyzes the physiological synthesis of CDP-diacylglycerol.
- 22 April 2009
- Published by Wolters Kluwer Health in NeuroReport
- Vol. 20 (6) , 606-610
Dopamine D1-like receptor activation induces brain-derived neurotrophic factor protein expression
Recent studies showed that dopamine or D1 receptor-selective agonists increased brain-derived neurotrophic factor (BDNF) mRNA and protein expression in neuronal cultures, and this action was blocked by SCH23390. Moreover, SKF38393 activated Trk receptors and downstream signaling in striatal neurons. This study examined whether dopamine agonists induce the expression of BDNF protein in rat brain tissue. Acute slice preparations were incubated with dopamine agonists in Hibernate A medium and BDNF protein was measured by a sensitive enzyme-linked immunosorbent assay. Results showed that dopamine increased BDNF in tissue slices after 24 h of incubation. Furthermore, SKF38393 produced a significant increase in BDNF protein in striatal and hippocampal tissue slices. These findings suggest that the induction of BDNF expression may constitute a downstream response to D1-like dopamine receptor activation.
- 22 April 2009
- Published by Wolters Kluwer Health in NeuroReport
- Vol. 20 (6) , 606-610
Dopamine D1-like receptor activation induces brain-derived neurotrophic factor protein expression
Recent studies showed that dopamine or D1 receptor-selective agonists increased brain-derived neurotrophic factor (BDNF) mRNA and protein expression in neuronal cultures, and this action was blocked by SCH23390. Moreover, SKF38393 activated Trk receptors and downstream signaling in striatal neurons. This study examined whether dopamine agonists induce the expression of BDNF protein in rat brain tissue. Acute slice preparations were incubated with dopamine agonists in Hibernate A medium and BDNF protein was measured by a sensitive enzyme-linked immunosorbent assay. Results showed that dopamine increased BDNF in tissue slices after 24 h of incubation. Furthermore, SKF38393 produced a significant increase in BDNF protein in striatal and hippocampal tissue slices. These findings suggest that the induction of BDNF expression may constitute a downstream response to D1-like dopamine receptor activation.
- 1 March 2009
- Published by Elsevier in Molecular Pharmacology
- Vol. 75 (3) , 447-453
D5 Dopamine Receptors are Required for Dopaminergic Activation of Phospholipase C
Dopamine activates phospholipase C in discrete regions of the mammalian brain, and this action is believed to be mediated through a D1-like receptor. Although multiple lines of evidence exclude a role for the D1 subtype of D1-like receptors in the phosphoinositide response, the D5 subtype has not been similarly examined. Here, mice lacking D5 dopamine receptors were tested for dopamine agonist-induced phosphoinositide signaling both in vitro and in vivo. The results show that hippocampal, cortical, and striatal tissues of D5 receptor knockout mice significantly or completely lost the ability to produce inositol phosphate or diacylglycerol messengers after stimulation with dopamine or several selective D1-like receptor agonists. Moreover, endogenous inositol-1,4,5-trisphosphate stimulation by the phospholipase C-selective D1-like agonist 3-methyl-6-chloro-7,8-dihydroxy-1-[3methylphenyl]-2,3,4,5-tetrahydro-1H-3-benzazepine (SKF83959) was robust in wild-type animals but undetectable in the D5 receptor mutants. Hence, D5 receptors are required for dopamine and selective D1-like agonists to induce phospholipase C-mediated phosphoinositide signaling in the mammalian brain.
- 1 March 2009
- Published by Elsevier in Molecular Pharmacology
- Vol. 75 (3) , 447-453
D5 Dopamine Receptors are Required for Dopaminergic Activation of Phospholipase C
Dopamine activates phospholipase C in discrete regions of the mammalian brain, and this action is believed to be mediated through a D1-like receptor. Although multiple lines of evidence exclude a role for the D1 subtype of D1-like receptors in the phosphoinositide response, the D5 subtype has not been similarly examined. Here, mice lacking D5 dopamine receptors were tested for dopamine agonist-induced phosphoinositide signaling both in vitro and in vivo. The results show that hippocampal, cortical, and striatal tissues of D5 receptor knockout mice significantly or completely lost the ability to produce inositol phosphate or diacylglycerol messengers after stimulation with dopamine or several selective D1-like receptor agonists. Moreover, endogenous inositol-1,4,5-trisphosphate stimulation by the phospholipase C-selective D1-like agonist 3-methyl-6-chloro-7,8-dihydroxy-1-[3methylphenyl]-2,3,4,5-tetrahydro-1H-3-benzazepine (SKF83959) was robust in wild-type animals but undetectable in the D5 receptor mutants. Hence, D5 receptors are required for dopamine and selective D1-like agonists to induce phospholipase C-mediated phosphoinositide signaling in the mammalian brain.